Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29639953 | 0.82 | PNMT (0.41) | DRD2DRD1 | |
| SCHEMBL20330372 | 0.82 | HTR2C (0.41) | DRD2DRD1 | |
| SCHEMBL4407148 | 0.82 | PNMT (0.41) | DRD2DRD1 | |
| Hydrochloric Acid SCHEMBL6608089 | 0.81 | PNMT (0.40) | DRD2DRD1 | |
| SCHEMBL16058900 | 0.75 | CYP1A2 (0.31) | CYP1A2 | |
| SCHEMBL3871102 | 0.75 | PNMT (0.37) | — | |
| SCHEMBL8008508 | 0.75 | KCNH2 (0.32) | — | |
| SCHEMBL1615486 | 0.75 | CHRNB2 (0.33) | — | |
| SCHEMBL30101455 | 0.75 | KCNH2 (0.38) | — | |
| SCHEMBL10100734 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| EP-3322417-B1 | TARGETING EMOPAMIL BINDING PROTEIN (EBP) WITH SMALL MOLECULES THAT INDUCE AN ABNORMAL FEEDBACK RESPONSE BY LOWERING ENDOGENOUS CHOLESTEROL BIOSYNTHESIS | UNIV TEXAS (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20210317111-A1 | NOVEL MEDICAMENT FOR TREATING INFLAMMATORY BOWEL DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-10-14 | — | — | US | disclosed |
| US-20210253571-A1 | AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR | WUXI LIFE FOUNTAIN BIOTECH CO., LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| WO-2021113686-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| EP-3825314-A1 | AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR | Medshine Discovery Inc. (CN) | 2021-05-26 | — | — | EP | disclosed |
| US-20210032207-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-02-04 | — | — | US | disclosed |
| US-10568888-B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | VTV THERAPEUTICS LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20150005287-A2 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-01 | — | — | US | disclosed |
| WO-2014128486-A1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | DOMAINEX LIMITED (GB) | 2014-08-28 | — | — | WO | disclosed |
| US-20140179675-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| US-20140179675-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| WO-2013029548-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-07 | — | — | WO | disclosed |
| US-20110160234-A1 | Tricyclic Compounds as Modulators of TNF-alpha Synthesis and as PDE4 Inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-06-30 | — | — | US | disclosed |
| US-7897628-B2 | {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-03-01 | — | — | US | disclosed |
| WO-2010025436-A2 | NITROGEN AND SULFUR-CONTAINING HETEROCYCLE DERIVATIVES | TRIAD MULTITECH PHARMACEUTICALS, INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| WO-2006099379-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006047302-A1 | BISSULFONAMIDE COMPOUNDS AS AGONISTS OF GALR1, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10568888-B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | PDE4A, PDE4B, TNF | DRD2 2285/4885DRD1 2004/4885CCR1 143/4885 |
| US-20110160234-A1 | Tricyclic Compounds as Modulators of TNF-alpha Synthesis and as PDE4 Inhibitors | PDE4A, PDE4B, TNF | DRD2 2435/4885DRD1 2177/4885CCR1 350/4885 |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | DRD2 4511/4885DRD1 4430/4885CCR1 2747/4885 |
| US-20150005287-A2 | QUINOLONE COMPOUND | HAX1, NQO2, VIP | DRD2 452/4885DRD1 116/4885CCR1 43/4885 |
| US-20210253571-A1 | AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR | MET, FGFR1, FGFR2 | DRD2 1778/4885DRD1 2141/4885CCR1 2713/4885 |
| US-20140179675-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | DRD2 449/4885DRD1 103/4885CCR1 51/4885 |
| US-20210032207-A1 | QUINOLONE COMPOUND | HAX1, NQO2, CXCR1 | DRD2 446/4885DRD1 101/4885CCR1 46/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | DRD2 4511/4885DRD1 4430/4885CCR1 2747/4885 |
| US-20210317111-A1 | NOVEL MEDICAMENT FOR TREATING INFLAMMATORY BOWEL DISEASE | FABP2, SLC10A2, NFKBIA | DRD2 4037/4885DRD1 4149/4885CCR1 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.